• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

EMA committee recommends approval for migraine prevention drug

June 1, 2018 By Sarah Faulkner

Novartis

Novartis (NYSE:NVS) said today that a committee for the European Medicines Agency has recommended that the regulatory agency approve Aimovig, a self-administered drug designed to prevent migraines in adults who have at least four migraine days each month.

The drug is the first of a new class of medicines, called CGRP inhibitors. It’s a monoclonal antibody that blocks the receptor for a protein that is linked to migraine pain, known as the calcitonin gene-related peptide. Just last month Aimovig, developed by Amgen (NSDQ:AMGN), won FDA approval in the U.S.

The product is designed to be administered once every four weeks using an auto-injector device. Novartis and Amgen plan to co-commercialize Aimovig in the U.S., but Amgen has exclusive rights in Japan. Novartis owns exclusive rights to commercialize in the rest of the world, including the E.U.

The EMA’s Committee for Medicinal Products for Human Use made its decision based on data from four Phase II and Phase III trials. Altogether, the late-stage trials enrolled more than 2,600 patients, according to Novartis. Across these studies, 50% of patients experiencing episodic migraine saw their number of migraine days cut in half after taking Aimovig.

“We are excited to be one step closer to bringing the first targeted migraine prevention therapy to patients in Europe,” Novartis Pharma CEO Paul Hudson said in prepared remarks. “If approved, patients suffering from migraine will no longer have to rely on preventive treatments repurposed from other diseases that are often associated with poor tolerability and lack of efficacy. With Aimovig, physicians may soon provide these patients with an option for a safe, effective and well-tolerated migraine prevention treatment.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Amgen, Novartis

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS